Log In
Print
BCIQ
Print
Print this Print this
 

ARX424

  Manage Alerts
Collapse Summary General Information
Company Ambrx Inc.
DescriptionLong acting pegylated version of interferon beta 1a (IFN-A)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation

Partner

Merck KGaA


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today